A research team at TooNiceStocks says Talon Therapeutics is launching its patented drug Marqibo, a nanoparticle packaged cancer therapy. The technology reduces toxicity while increasing efficiency.
At present, the indication is for adults suffering from Philadelphia chromosome (Ph) negative acute lymphoblastic leukemia (ALL) in relapse for the second time, or where it has progressed after multiple anti-leukemia treatments could expand to other types of ALL. The company will shortly apply for a new drug application (NDA) to the Food and Drug Administration (FDA.
The research revealed poor prognosis in patients and these treatments are restricted because of residual toxicity from earlier therapies. Third level treatments generated little responses while showing high toxicity. Treatments beyond this level displayed even more toxicity with no responses.
Marqibo contains vincristine sulfate enclosed in the water core of the in-house sphingomyelin-based liposome called Optisomes. Vincristine sulfate is a cancer drug approved by FDA and is used to treat ALL. But Optisomes used with vincristine sulfate enhances advantages. It is possible to administer the vincristine sulfate in larger doses to ensure improved targeting and penetration, while lowering toxicity.
The analysts discovered that Talon’s Phase II RALLY research revealed that Marqibo was efficient. The drug was administered to 65 patients as a third, fourth or fifth level treatment. It was seen that 35% displayed overall response rate and 20% displayed complete response rate. Of the complete responses, 62% responded over longer periods than to earlier therapies. Over a week, 63% patients revealed that all cancer presence from their blood had been removed. Patients suffering from organ leukemia showed a reversal of organ dysfunction with complete response.
This research will enable Talon to apply for a quick review to help it commence Phase III trials of Marqibo in ALL.
Source: http://www.TooNiceStocks.com